1. Home
  2. MGRC vs BEAM Comparison

MGRC vs BEAM Comparison

Compare MGRC & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo McGrath RentCorp

MGRC

McGrath RentCorp

SELL

Current Price

$127.61

Market Cap

2.7B

ML Signal

SELL

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

SELL

Current Price

$20.91

Market Cap

2.8B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
MGRC
BEAM
Founded
1979
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.8B
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
MGRC
BEAM
Price
$127.61
$20.91
Analyst Decision
Buy
Strong Buy
Analyst Count
3
15
Target Price
★ $147.80
$49.85
AVG Volume (30 Days)
481.8K
★ 1.8M
Earning Date
10-28-2026
11-03-2026
Dividend Yield
★ 1.54%
N/A
EPS Growth
N/A
★ 82.31
EPS
★ 4.46
N/A
Revenue
★ $944,235,000.00
$24,000.00
Revenue This Year
$0.97
N/A
Revenue Next Year
$4.34
N/A
P/E Ratio
$28.78
★ N/A
Revenue Growth
3.65
★ 33.33
52 Week Low
$94.99
$20.23
52 Week High
$134.61
$38.26

Technical Indicators

Market Signals
Indicator
MGRC
BEAM
Relative Strength Index (RSI) 59.89 34.74
Support Level $105.55 N/A
Resistance Level $134.61 $28.19
Average True Range (ATR) 4.61 1.94
MACD 0.08 -0.54
Stochastic Oscillator 61.33 0.22

Price Performance

Historical Comparison
MGRC
BEAM

About MGRC McGrath RentCorp

McGrath RentCorp is a diversified business-to-business rental company with three rental divisions: relocatable modular buildings, portable storage containers, and electronic test equipment. It comprises four reportable business segments, namely the Modular Building segment (Mobile Modular), which generates maximum revenue; the Portable Storage segment (Portable Storage); the Electronic Test Equipment segment (TRS-RenTelco); and its classroom manufacturing business (Enviroplex), which sells modular buildings used as classrooms in California. The company generates its revenues mainly from the rental of its equipment under operating leases, with sales of equipment occurring in the normal course of business.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Share on Social Networks: